RIGEL PHARMACEUTICALS, INC. Expense Breakdown
No Expense Breakdown for RIGL on this site yet.
- 2026-06-30: One Operating $8.53M.
- 2025-06-30: One Operating $4.50M.
Source checked: the stored Expense Breakdown page for RIGL.
Expenses by product
Cost of sales: each quarter (3 month)
| Quarter end | One Operating |
|---|---|
| 2026-06-30 | $8.53M |
| 2025-06-30 | $4.50M |
Income Tax Expense (Benefit): each quarter (3 month)
| Quarter end | One Operating |
|---|---|
| 2026-06-30 | $6.29M |
| 2025-06-30 | $369.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |